Moderna Inc (MRNA) Government Trades - Latest Congressional Stock Transactions
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
top performing (MRNA) trades
Daniel Goldman
House (D-NY)
-19.60%
Robert Bresnahan
House (R-PA)
-24.10%
Josh Gottheimer
House (D-NJ)
-30.40%
Recent Moderna (MRNA) Trades by Congress Members
See the most up-to-date Moderna trades disclosed by US lawmakers, including purchase and sale amounts, transaction dates, and reporting details. View the most recent Moderna trades made by congress members.
Robert BresnahanHouse (R-PA) | $1K - $15K | stock | Sale | Apr 08, 2025 | House | |
Robert BresnahanHouse (R-PA) | $1K - $15K | stock | Purchase | Feb 25, 2025 | House | |
 Julie JohnsonHouse (D-TX) | $1K - $15K | stock | Sale | Jan 15, 2025 | House | |
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Sale | Feb 01, 2024 | House | |
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Sale | Sep 15, 2023 | House | |
Daniel GoldmanHouse (D-NY) | $50K - $100K | stock | Sale | Jul 12, 2023 | House | |
Daniel GoldmanHouse (D-NY) | $50K - $100K | stock | Purchase | Apr 10, 2023 | House | |
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Purchase | Mar 31, 2023 | House | |
Daniel GoldmanHouse (D-NY) | $50K - $100K | stock | Sale | Mar 06, 2023 | House |
